Benralizumab
Modify Date: 2024-01-05 17:17:39
Benralizumab structure
|
Common Name | Benralizumab | ||
|---|---|---|---|---|
| CAS Number | 1044511-01-4 | Molecular Weight | 146054.0 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C6492H10060N1724O2028S42 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BenralizumabBenralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used to treat severe eosinophilic asthma[1]. |
| Name | Benralizumab |
|---|
| Description | Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used to treat severe eosinophilic asthma[1]. |
|---|---|
| Related Catalog | |
| Target |
IL-5Rα[1] |
| References |
| Molecular Formula | C6492H10060N1724O2028S42 |
|---|---|
| Molecular Weight | 146054.0 |